The type A botulinal toxin assay by the reverse passive hemagglutination procedure which uses antitoxin to crystalline toxin was examined for specificity. The analysis was based on the fact that crystalline type A toxin is a complex of neurotoxic protein (Aa) and a nontoxic protein (AB). By using these components, obtained in essentially pure forms, it was shown that the antitoxin to crystalline toxin has a significantly higher titer to A/i than to Aa. When Formalin-treated red blood cells were sensitized with this antitoxin, the antibodies coupled to the cells were, for practical results, only anti-A/i. When the suspension is reacted with dilutions of type A toxic solutions, the limiting dilutions are determined by A/i and not by the neurotoxin, which should be the determinant if the assay is to measure toxicity. These observations may be pertinent to the development of serological assays for other botulinal toxin types.
The several studies on the assay of botulinal toxin by in vitro serological procedures are predicated on the specific reaction of toxin with its antitoxin (9, 14, 17) . Although there was early recognition that toxin neutralizing antibodies seemed unrelated to the end points of some of these tests (10) , recent reports do not always present convincing evidence that the procedure being studied is specific for the neurotoxic antigen.
The latest example is the assay of type A toxin by a reverse passive hemagglutination (RPH) test which used antitoxin to crystalline type A toxin (8) . In the procedure a suspension of red blood cells, to which antitoxin had been coupled, was added to dilutions of toxin. Toxin concentration in the test sample was calculated from a comparison of the limiting dilutions of the sample and of the standard crystalline toxin solution of known concentration.
The purpose of the present communication is to present evidence that the test is based on reaction of a nontoxic protein instead of the neurotoxic protein. The approach can be understood best from a summary of what is known about crystalline type A botulinal toxin. Acidic solutions of this toxic preparation behave in certain physicochemical tests as a homogeneous preparation (15) . Nevertheless, in addition to botulinal toxicity it possesses hemagglutinat-' On leave from: Department of Veterinary Science, College of Agriculture, University of Osaka Prefecture, Osaka, Japan.
ing activity. The two activities can be separated when crystalline toxin as alkaline solutions is absorbed with erythrocytes (13) or subjected to ultracentrifugation (18) or ion exchange chromatography (4). The isolated neurotoxic protein of 150,000 molecular weight has greater specific toxicity than the starting crystalline toxin of 900,000 molecular weight. Crystalline toxin is a complex of neurotoxin (a component) and hemagglutinin (IB component) which are held together by means other than covalent bonds.
The Aa to A/f ratio (wt/wt) in crystalline toxin is 1 to 4 (4) or, possibly, 1 to 9 (1).
The two proteins constituting the crystalline toxin have different amino acid compositions (1) and are antigenically distinct (13) ; antitoxin resulting from immunization with toxoided crystalline toxin gives two immune precipitate lines when it is reacted against crystalline toxin in Ouchterlony double-diffusion serology (4 (9) . After the coupling reaction, the cells were washed with 0.15 M sodium phosphate buffer, pH 7.3, and made into a 0.5% suspension in PBS containing 0.25% bovine serum albumin, fraction V (Nutritional Biochemicals, Cleveland, Ohio).
The IgG solution to be used for coupling was diluted to contain 800 hemagglutinating units per ml. The arbitrary hemagglutinating unit is the minimum antitoxin amount which is required to agglutinate a Aa-sensitized cell suspension (see below). For the particular IgG preparation being used, about 1 antitoxin IU equaled 400 hemagglutinating units. Use of this antitoxin concentration for the coupling step gave cell suspensions which were maximally sensitized for agglutination by the neurotoxin antigen.
Purified Aa could be used directly, but crystalline toxin and A,6 had to be prepared (incubation in final 0.4% Formalin for 1 week at 37 C, followed by dialysis against PBS) for coupling to Formalinized RBC. Without the treatment, the sensitized cell suspensions were not suitable for the tests. Antigen solutions used in the coupling reaction had protein concentrations of 10 to 20 ug/ml. RPH test. A microtitration procedure was used.
Serial, twofold antigen dilutions of 50-,gliter volumes were prepared in U-bottomed wells of titration plates by using microdiluters (Cooke Engineering Co., Alexandria, Va. Crystalline toxin 19 aReciprocal of highest antitoxin dilution causing hemagglutination; numbers are logarithms to base 2.
should be the effective antigen if the purpose of the procedure is assessment of toxicity, does not play a significant role. The fact that neurotoxin can be calculated or shown by mouse tests to be present in the titer dilution is not proof that it is the determinant of the titer. Similarly, the reported correlation between RPH titers and toxicities (8) is not evidence that the test measures neurotoxin; the titer would change proportionately with the AO concentration.
Indirect assay of neurotoxin in crystalline toxin preparations seems possible. Crystalline toxin preparations, routinely prepared with a particular culture strain, have the same Aa to Ad ratio, because they all have the same specific toxicities. Thus, the AB titer could be obtained by the RPH test and then be converted into Aa titer by using this ratio.
It is not known if all type A cultures produce the same Aa to Af3 ratio or if the ratio in crystalline toxin is the same as in the culture fluid from which the crystals are derived. If not, quantitation of neurotoxin in toxic culture fluids with the indirect approach could give significant errors.
When antitoxin to crystalline toxin is used in serological procedures other than RPH tests, the same specificity problem must be resolved. The obvious solution would be use of antiserum which is monospecific for Aa. The recently reported radioimmunoassay procedure (2) utilized such an antitoxin.
The botulinogenic entities in culture fluids of the several Clostridium botulinum types tested (A through F) behaved during ultracentrifugation as molecules of at least several hundred thousand molecular weight (16) . Type B and E toxin preparations, which are essentially homogeneous in acidic conditions, have been prepared and shown to be composed of units of 500,000 (7) and 350,000 (11) molecular weight, respectively. However, these are molecular complexes similar to crystalline type A toxin in that a neurotoxic protein is associated with a nontoxic protein. The purified type B neurotoxin is of 165,000 molecular weight (5) and type E neurotoxin of 150,000 molecular weight (11) . It follows that the present discussion on type A toxin assay is relevant to in vitro serological assay procedures for type B and E toxins when antitoxins to the large toxic complexes are used.
